{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:51:45Z","timestamp":1781891505644,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.retram.2026.103590","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:42:58Z","timestamp":1778481778000},"page":"103590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Abdel-Razeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2026.103590_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103590_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103590_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.retram.2026.103590_bib0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.retram.2026.103590_bib0005","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.retram.2026.103590_bib0006","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103590_bib0007","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene Maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2026.103590_bib0008","doi-asserted-by":"crossref","first-page":"S1006","DOI":"10.1016\/S2152-2650(25)02763-6","article-title":"CT-230: lisocabtagene Maraleucel (liso-cel) in patients with relapsed or refractory (R\/R) marginal zone lymphoma (MZL) in the phase 2 TRANSCEND FL study","volume":"25","author":"Palomba","year":"2025","journal-title":"Clinic Lymph Myel Leuke"},{"key":"10.1016\/j.retram.2026.103590_bib0009","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103590_bib0010","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.retram.2026.103590_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-025-02541-1","article-title":"Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study","author":"Kharfan-Dabaja","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.retram.2026.103590_bib0012","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103590_bib0013","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41375-025-02582-x","article-title":"Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy","volume":"39","author":"Iacoboni","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2026.103590_bib0014","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jtct.2025.08.008","article-title":"Treatment of diffuse large B-cell lymphoma progressing or relapsing after chimeric antigen receptor T-cell therapy","volume":"31","author":"Kharfan-Dabaja","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.retram.2026.103590_bib0015","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2026.103590_bib0016","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103590_bib0017","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.retram.2026.103590_bib0018","unstructured":"Wells G., Shea B., O\u2019Connell D., et al. The newcastle-ottawa scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa, Ontario: University of Ottawa."},{"key":"10.1016\/j.retram.2026.103590_bib0019","unstructured":"STATA. 18.5 ed. College Station, TX: StataCorp LLC; 2023."},{"key":"10.1016\/j.retram.2026.103590_bib0020","series-title":"Cochrane handbook for systematic reviews of interventions. version 6.5 ed","article-title":"Chapter 10: analysing data and undertaking meta-analyses","author":"Deeks","year":"2024"},{"key":"10.1016\/j.retram.2026.103590_bib0021","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.retram.2026.103590_bib0022","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2026.103590_bib0023","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103590_bib0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.retram.2026.103590_bib0025","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s43018-025-00941-2","article-title":"Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study","volume":"6","author":"Cartron","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.retram.2026.103590_bib0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bjh.19057","article-title":"Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas","volume":"204","author":"Dodero","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2026.103590_bib0027","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1182\/blood-2023-186033","article-title":"Efficacy and safety of Glofitamab in patients with R\/R DLBCL in real life setting - a retrospective study","volume":"142","author":"Gurion","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103590_bib0028","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2022-169219","article-title":"Salvage treatment with novel agents is preferable to standard chemotherapy in patients with large B-cell lymphoma progressing after chimeric antigen receptor T-cell therapy","volume":"140","author":"Iacoboni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103590_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.62","article-title":"Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy","volume":"8","author":"Iacoboni","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.retram.2026.103590_bib0030","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2026.103590_bib0031","article-title":"Safety and efficacy of Glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","author":"Shumilov","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2026.103590_bib0032","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2026.103590_bib0033","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab monotherapy in R\/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study","volume":"145","author":"Topp","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103590_bib0035","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103590_bib0036","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood-2025-398","article-title":"Impact of sequencing of CART vs bi-specific antibody on survival in relapsed\/refractory large B-cell lymphoma: an analysis from the ABC consortium","volume":"146","author":"Kelsten","year":"2025","journal-title":"Blood"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:57:07Z","timestamp":1781888227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2452318626000267"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103590","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103590"}}